We assert that by deploying inhibitors of FOXM1, we may be able to downregulate the expansive transcriptional network that FOXM1 helms, which might confer significant clinical benefits for AR-low TNBC and/or QNBC patients, improve their disease outcomes, and aid in the amelioration of persistent racial disparities in breast cancer outcomes. Here, FOXM1 is linked to breast cancer.